# Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

> **NCT06220097** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 28 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B-cell Lymphoma Refractory

## Interventions

- **DRUG:** Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells

## Key facts

- **NCT ID:** NCT06220097
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-12-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06220097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06220097, "Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06220097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*